World's Best Scientists 2026 revealed!
Miguel A. Sanz

Miguel A. Sanz

Award Badge
Medicine
Spain
2023

D-Index & Metrics

Medicine

D-Index
97
Citations
65419
World Ranking
9064
National Ranking
130

Miguel A. Sanz publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Miguel A. Sanz sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 807 publications — 87th percentile

87% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Miguel A. Sanz D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Miguel A. Sanz sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 97 D-Index — 55th percentile

55% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2023 - Research.com Medicine in Spain Leader Award

Overview

Miguel A. Sanz is affiliated with the University of Valencia in Spain and has a research focus primarily within the field of Medicine, with a strong specialization in Hematology. Their body of work encompasses a variety of related subfields including Molecular Biology, Genetics, Oncology, and Public Health, Environmental and Occupational Health.

The topics covered in Miguel A. Sanz's research reflect a concentration on hematologic disorders and treatment approaches, including:

  • Acute Myeloid Leukemia Research
  • Hematopoietic Stem Cell Transplantation
  • Retinoids in leukemia and cellular processes
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Multiple Myeloma Research and Treatments
  • Acute Lymphoblastic Leukemia research
  • Histone Deacetylase Inhibitors Research

The scientist has contributed to various publication venues, with several papers appearing frequently in the following journals and platforms:

  • Blood
  • Cancers
  • Transplantation and Cellular Therapy
  • Clinical Lymphoma Myeloma & Leukemia
  • Bone Marrow Transplantation

Some of Miguel A. Sanz's recent papers include:

  • "Acute Promyelocytic Leukemia: A Constellation of Molecular Events around a Single PML-RARA Fusion Gene," 2020, published in Cancers
  • "Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial," 2021, published in Leukemia
  • "Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results," 2021, published in Leukemia
  • "Lactobacillus supports Clostridiales to restrict gut colonization by multidrug-resistant Enterobacteriaceae," 2022, published in Nature Communications
  • "Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study," 2021, published in Blood Advances

Their frequent co-authors comprise a network of scientists with whom they have collaborated extensively over multiple publications, including:

  • Pau Montesinos
  • David Martínez-Cuadrón
  • Jaime Sanz
  • Juan Montoro
  • Aitana Balaguer-Roselló

Best Publications

  • Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

    Hartmut Döhner;Elihu Estey;David Grimwade;Sergio Amadori

  • International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

    Peter Greenberg;Christopher Cox;Michelle M. LeBeau;Pierre Fenaux

  • Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

    Hartmut Dohner;Elihu H. Estey;Sergio Amadori;Frederick R. Appelbaum

  • Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

    Bruce D. Cheson;John M. Bennett;Kenneth J. Kopecky;Thomas Büchner

  • Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

    Francesco Rodeghiero;Roberto Stasi;Terry Gernsheimer;Marc Michel

  • International consensus report on the investigation and management of primary immune thrombocytopenia.

    Drew Provan;Roberto Stasi;Adrian C. Newland;Victor S. Blanchette

  • Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

    Richard M. Stone;Sumithra J. Mandrekar;Ben L. Sanford;Kristina Laumann

  • Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

    Hagop M Kantarjian;Anthony Stein;Nicola Gökbuget;Adele K. Fielding

  • Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

    Miguel A. Sanz;David Grimwade;Martin S. Tallman;Bob Lowenberg

  • A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia

    Pierre Fenaux;Claude Chastang;Sylvie Chevret;Miguel Sanz

  • Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

    David J. Kuter;James B. Bussel;Roger M. Lyons;Vinod Pullarkat

  • Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups.

    Miguel A. Sanz;Francesco Lo Coco;Guillermo Martı́n;Giuseppe Avvisati

  • Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group

    Miguel A. Sanz;Guillermo Martín;Marcos González;Angel León

  • A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group.

    Miguel A. Sanz;Guillermo Martı́n;Consuelo Rayón;Jordi Esteve

  • Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients.

    GF Sanz;MA Sanz;T Vallespi;MC Canizo

  • Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet

    Miguel A. Sanz;Miguel A. Sanz;Pierre Fenaux;Martin S. Tallman;Elihu H. Estey

  • Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

    Mark Levis;Farhad Ravandi;Eunice S. Wang;Maria R. Baer

  • Primary Plasma Cell Leukemia: Clinical, Immunophenotypic, DNA Ploidy, and Cytogenetic Characteristics

    R. Garcı́a-Sanz;A. Orfão;M. González;M.D. Tabernero

  • Incidence, Clinical Features, and Outcome of AllTrans-Retinoic Acid Syndrome in 413 Cases of Newly Diagnosed Acute Promyelocytic Leukemia

    S. De Botton;H. Dombret;M. Sanz;J. San Miguel

  • Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin.

    Javier de Serna;Pau Montesinos;Edo Vellenga;Chelo Rayón

Frequent Co-Authors

Guillermo Sanz
Guillermo Sanz Hospital Universitari i Politècnic La Fe
Francesco Lo-Coco
Francesco Lo-Coco University of Rome Tor Vergata
Bob Löwenberg
Bob Löwenberg Erasmus MC
Martin S. Tallman
Martin S. Tallman Northwestern University
Pierre Fenaux
Pierre Fenaux Université Paris Cité
Arnold Ganser
Arnold Ganser Hannover Medical School
Marcos González
Marcos González University of Salamanca
Raul C. Ribeiro
Raul C. Ribeiro St. Jude Children's Research Hospital
David Grimwade
David Grimwade King's College London
Hartmut Döhner
Hartmut Döhner University of Ulm

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens numerous related online degree and career opportunities. For those with an associate’s degree in nursing, adn to fnp bridge programs offer a flexible path to advanced clinical roles, making it easier to become a Family Nurse Practitioner.

Students interested in broader health topics may benefit from pursuing an online degree nutrition program. These programs can lead to careers in dietetics, wellness coaching, and public health education.

For those looking to move into management and leadership, top cahme accredited mha programs prepare graduates for administrative roles within hospitals and healthcare systems.

Registered nurses can advance their education seamlessly with rn to bsn online without clinicals options, allowing working professionals to qualify for more job opportunities and higher pay with full schedule flexibility.

Best Scientists Citing Miguel A. Sanz

Trending Scientists

Recently Published Articles